作者: Jan Stoehlmacher
DOI: 10.1007/978-3-540-46091-6_8
关键词:
摘要: Treatment of gastrointestinal cancers has significantly advanced over the last several years with introduction effective chemotherapeutic and targeted drugs. Providing individual treatment low toxicity but maximum benefit is still an unsolved problem. Inter-individual variation drug efficacy mainly determined by genetic polymorphisms. The approach pharmacogenetics pharmacogenomics developing as a valuable tool to design tailored therapy. This review focuses on clinically significant polymorphisms in genes involved metabolism chemotherapy used cancer: fluoropyrimidines, irinotecan, platinum. In addition, first results therapy including cetuximab bevacizumab are discussed.